Evidence map›Paper›PMID 34681603›Full record

ReviewInternational journal of molecular sciences2021

Ferroptosis: At the Crossroad of Gemcitabine Resistance and Tumorigenesis in Pancreatic Cancer.

Jianhui Yang, Jin Xu, Bo Zhang, Zhen Tan, Qingcai Meng, Jie Hua, Jiang Liu, Wei Wang, Si Shi, Xianjun Yu and 1 more

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 63 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Jianhui YangDepartment of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Jin XuDepartment of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Bo ZhangDepartment of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Zhen TanDepartment of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Qingcai MengDepartment of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Jie HuaDepartment of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Jiang LiuDepartment of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Wei WangDepartment of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Si ShiDepartment of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.ORCID 0000-0002-6652-0629
Xianjun YuDepartment of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Chen LiangDepartment of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Shanghai Medical College of Fudan University · CN

Funding

Clinical and Scientific Innovation Project of Shanghai Hospital Development Center SHDC12018109Clinical Research Plan of Shanghai Hospital Development Center SHDC2020CR1006ANational Natural Science Foundation of China 81772555National Natural Science Foundation of China 81802352National Natural Science Foundation of China 81902428National Science Foundation for Distinguished Young Scholars ofChina No. 81625016Scientific Innovation Project of Shanghai Education Committee 2019-01-07-00-07-E00057Shanghai Sailing Program No.19YF1409400
6 · The paper itself

Abstract

The overall five-year survival rate of pancreatic cancer has hardly changed in the past few decades (less than 10%) because of resistance to all known therapies, including chemotherapeutic drugs. In the past few decades, gemcitabine has been at the forefront of treatment for pancreatic ductal adenocarcinoma, but more strategies to combat drug resistance need to be explored. One promising possibility is ferroptosis, a form of a nonapoptotic cell death that depends on intracellular iron and occurs through the accumulation of lipid reactive oxygen species, which are significant in drug resistance. In this article, we reviewed gemcitabine-resistance mechanisms; assessed the relationship among ferroptosis, tumorigenesis and gemcitabine resistance, and explored a new treatment method for pancreatic cancer.

Indexed as

FerroptosisCarcinoma, Pancreatic DuctalDeoxycytidineDrug Resistance, NeoplasmGemcitabineHumansMicroRNAsPancreatic NeoplasmsPhospholipid Hydroperoxide Glutathione PeroxidaseReactive Oxygen SpeciesSignal TransductionDeoxycytidineGemcitabineMicroRNAsPhospholipid Hydroperoxide Glutathione PeroxidaseReactive Oxygen Speciesferroptosisgemcitabine resistanceNRF2pancreatic ductal adenocarcinomaROS

Identifiers

PMID34681603
PMCPMC8539929
OpenAlexW3207717279

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.